Decoy Therapeutics Inc., a biotechnology company incorporated in Delaware on February 26, 2014, and its operations are primarily located in Boston, Massachusetts. The company is a clinical-stage biopharmaceutical company focused on developing innovative treatment options for cancer patients. Its product portfolio includes seclidemstat, a lead drug candidate currently in a Phase 1/2 clinical study at MD Anderson Cancer Center, designed to target hematological cancers such as myelodysplastic syndrome (MDS) and chronic myelomonocytic leukemia (CMML), especially for patients with limited treatment options. In addition, the company is also advancing SP-3164, an oral small molecule protein degrading agent, which is currently in the new drug research phase (IND). 

DCOY

DCOY Profile